Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	391210-10-9
Formula :	C₁₆H₁₄F₃IN₂O₄
M.W :	482.19
SMILES Code :	O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO
Synonyms :	PD0325901; PD325901
MDL No. :	MFCD08435926
InChI Key :	SUDAHWBOROXANE-SECBINFHSA-N
Pubchem ID :	9826528

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H373-H410
Precautionary Statements:	P273-P301+P310
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

WU-225	10 µM	2 h	Evaluate the inhibitory effect of Mirdametinib on WU-225 microtissues, results showed that Mirdametinib significantly inhibited the growth of WU-225 microtissues.	Neuro Oncol. 2023 Nov 2;25(11):2044-2057.
JH-2-079-c	10 µM	2 h	Evaluate the inhibitory effect of Mirdametinib on JH-2-079-c microtissues, results showed that Mirdametinib significantly inhibited the growth of JH-2-079-c microtissues.	Neuro Oncol. 2023 Nov 2;25(11):2044-2057.
JH-2-002	10 µM	2 h	Evaluate the inhibitory effect of Mirdametinib on JH-2-002 microtissues, results showed that Mirdametinib significantly inhibited the growth of JH-2-002 microtissues.	Neuro Oncol. 2023 Nov 2;25(11):2044-2057.
MN-2	10 µM	2 h	Evaluate the inhibitory effect of Mirdametinib on MN-2 microtissues, results showed that Mirdametinib significantly inhibited the growth of MN-2 microtissues.	Neuro Oncol. 2023 Nov 2;25(11):2044-2057.
K562-R cells	0.5 μM	3 h	Mirdametinib significantly increased ATO-induced cell death in TKI-resistant primary blasts derived from patients with CML or ALL.	Leukemia. 2023 Aug;37(8):1671-1685.
Ba/F3p210T315I cells	0.5 μM	3 h	The combination of Mirdametinib and ATO synergistically induced apoptosis in all tested cell lines, regardless of their sensitivity to TKIs.	Leukemia. 2023 Aug;37(8):1671-1685.
JHH-136	10 nM	72 h	To evaluate the effect of Mirdametinib combined with radiation, results showed that combined therapy significantly inhibited cell growth and sphere formation in NF1-deficient neurospheres.	Mol Cancer Ther. 2024 Sep 4;23(9):1261-1272.
HSR-GBM1	10 nM	72 h	To evaluate the effect of Mirdametinib combined with radiation, results showed that combined therapy significantly inhibited cell growth and sphere formation in NF1-deficient neurospheres.	Mol Cancer Ther. 2024 Sep 4;23(9):1261-1272.
Calu-6	3 µM		BGB-283 significantly enhanced the antiproliferative activity of PD-0325901, with a 59-fold decrease in EC50.	Mol Oncol. 2020 Aug;14(8):1833-1849.

Mice	NRG mice	Oral	1.5 mg/kg	Daily for 5-6 weeks	Evaluate the inhibitory effect of Mirdametinib on MPNST tumor growth in NRG mice, results showed that Mirdametinib significantly inhibited tumor growth.	Neuro Oncol. 2023 Nov 2;25(11):2044-2057.
Mice	BCR::ABL1-T315I-induced leukemia model	Oral	10 mg/kg	Continued for 3 weeks	The combination of Mirdametinib and ATO significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia and reduced tumor cell infiltration.	Leukemia. 2023 Aug;37(8):1671-1685.
Mice	BTBR mice	Intraperitoneal injection	1 mg/kg, 10 mg/kg, 25 mg/kg	Once daily for 11 days	To evaluate the effects of Mirdametinib on core symptoms of autism. Results showed that Mirdametinib dose-dependently reduced social deficits, vocalization abnormalities, and repetitive behaviors in BTBR mice, and reversed abnormal EEG signals.	EBioMedicine. 2023 May;91:104565
NSG mice	Heterotopic xenograft models	Oral gavage	1.5 mg/kg	Twice daily for 4 weeks	To evaluate the effect of Mirdametinib combined with radiation, results showed that combined therapy significantly inhibited tumor growth in NF1-deficient heterotopic xenograft models.	Mol Cancer Ther. 2024 Sep 4;23(9):1261-1272.
Mice	Calu-6 NSCLC xenograft model	Oral	25 mg/kg	Twice daily for 28 days	The combination of BGB-283 and selumetinib showed enhanced antitumor efficacy in suppressing tumor growth and resulted in partial and complete tumor regression.	Mol Oncol. 2020 Aug;14(8):1833-1849.

{[proInfo.proName]}

CAS No.: 391210-10-9

{[proInfo.proName]}

CAS No.: 391210-10-9

Alternative Products

Product Details of Mirdametinib

Safety of Mirdametinib

Related Pathways of Mirdametinib

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03170206	Lung Cancer	Phase 1 Phase 2	Recruiting	March 31, 2024	United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Geoffrey Shapiro, MD, PhD 617-632-4942 Principal Investigator: Geoffrey Shapiro, MD Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Rebecca Heist, MD 617-726-1838 Principal Investigator: Rebecca Heist, MD Less <<
NCT02510001	Solid Tumor C... More >>olorectal Cancer Less <<	Phase 1	Active, not recruiting	September 2019	United Kingdom ... More >> Oxford University Hospital NHS Trust Oxford, United Kingdom, OX3 7LE Less <<
NCT01347866	-		Terminated(Refer to Detailed D... More >>escription for documentaion of Termination Statement.) Less <<	-	-
NCT01347866	Advanced Cancer	Phase 1	Terminated(Refer to Detailed D... More >>escription for documentaion of Termination Statement.) Less <<	-	United States, California ... More >> Ronald Reagan UCLA Medical Center Los Angeles, California, United States, 90095-6984 Ronald Reagan UCLA Medical Center Los Angeles, California, United States, 90095 UCLA Medical Center Los Angeles, California, United States, 90095 UCLA Oncology Center Los Angeles, California, United States, 90095 Santa Monica - UCLA Medical Center and Orthopaedic Hospital Santa Monica, California, United States, 90404 UCLA Santa Monica Hematology Oncology Santa Monica, California, United States, 90404 United States, Colorado Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 University of Colorado Denver (CTRC) Aurora, Colorado, United States, 80045 University of Colorado Hospital Anschutz Inpatient Pavilion Aurora, Colorado, United States, 80045 University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, South Carolina Medical University of South Carolina, Hollings Cancer Center Charleston, South Carolina, United States, 29425 Medical University of South Carolina Charleston, South Carolina, United States, 29425 MUSC, Investigational Drug Services Charleston, South Carolina, United States, 29425 MUSC Health East Cooper Mount Pleasant, South Carolina, United States, 29464 MUSC Specialty Care-North North Charleston, South Carolina, United States, 29406 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Italy Ospedale San Raffaele Milano, Italy, 20132 Spain Hospital General Vall d'Hebron Barcelona, Spain, 08035 Less <<
NCT00147550	Melanoma Colo... More >>nic Neoplasms Breast Neoplasms Less <<	Phase 1 Phase 2	Terminated(See termination rea... More >>son in detailed description.) Less <<	-	United States, Alabama ... More >> Pfizer Investigational Site Birmingham, Alabama, United States, 35233-2115 Pfizer Investigational Site Birmingham, Alabama, United States, 35233 Pfizer Investigational Site Birmingham, Alabama, United States, 35294 United States, California Pfizer Investigational Site La Jolla, California, United States, 92037 Pfizer Investigational Site La Jolla, California, United States, 92093 Pfizer Investigational Site La Mesa, California, United States, 91942 Pfizer Investigational Site Los Angeles, California, United States, 90025 Pfizer Investigational Site San Diego, California, United States, 92103 Pfizer Investigational Site San Diego, California, United States, 92123 Pfizer Investigational Site Santa Monica, California, United States, 90404 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Michigan Pfizer Investigational Site Detroit, Michigan, United States, 48201 Pfizer Investigational Site Detroit, Michigan, United States, 48202 United States, Minnesota Pfizer Investigational Site Rochester, Minnesota, United States, 55905 United States, New York Pfizer Investigational Site New York, New York, United States, 10021 Pfizer Investigational Site New York, New York, United States, 10022 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44106 Less <<
NCT00174369	Carcinoma, Non-Small-Cell Lung	Phase 2	Terminated(Terminated [See Det... More >>ailed Description for Termination Reason.]) Less <<	-	United States, California ... More >> Pfizer Investigational Site Greenbrae, California, United States, 94904 Pfizer Investigational Site La Jolla, California, United States, 92093 Pfizer Investigational Site LaJolla, California, United States, 92037 Pfizer Investigational Site San Diego, California, United States, 92103 Pfizer Investigational Site San Mateo, California, United States, 94402 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Michigan Pfizer Investigational Site Ann Arbor, Michigan, United States, 48106-0995 Pfizer Investigational Site Detroit, Michigan, United States, 48201 Pfizer Investigational Site Farmington Hills, Michigan, United States, 48334 United States, Minnesota Pfizer Investigational Site Coon Rapids, Minnesota, United States, 55433 Pfizer Investigational Site Fridley, Minnesota, United States, 55432 Pfizer Investigational Site Robbinsdale, Minnesota, United States, 55422 United States, New York Pfizer Investigational Site New York, New York, United States, 11725 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT02297802	-		-	-	United States, California ... More >> Sharp Healthcare San Diego, California, United States, 92123 Less <<
NCT02039336	Colorectal Cancer	Phase 1 Phase 2	Recruiting	December 2019	Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066CX Contact: F opdam, MD, PhD +31 20 512 2446 f.opdam@nki.nl Erasmus Medical Center Cancer Institute Recruiting Rotterdam, Netherlands, 3015CE University Medical Center Utrecht Recruiting Utrecht, Netherlands, 3584CX Less <<
NCT02096471	Neurofibromatosis Type 1 and G... More >>rowing or Symptomatic, Inoperable PN Less <<	Phase 2	Active, not recruiting	December 2018	United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Indiana Indiana Unversity Indianapolis, Indiana, United States, 46202 United States, Maryland National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, Missouri Washington University - St. Louis Saint Louis, Missouri, United States, 63110 United States, New York New York University Medical Center New York, New York, United States, 10016 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19096 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 Less <<
NCT02022982	KRAS Mutant Non-Small Cell Lun... More >>g Cancer Solid Tumors Less <<	Phase 1 Phase 2	Active, not recruiting	December 2020	United States, Massachusetts ... More >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT06153173	Langerhans Cell Histiocytosis ... More >>(LCH)\|Juvenile Xanthogranuloma (JXG)\|Rosai-Dorfman Disease (RDD)\|Histiocytic Disorders Less <<	PHASE2	RECRUITING	2025-03-31	Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT06159166	NF1\|Cutaneous Neurofibroma\|Mon... More >>otherapy Less <<	PHASE1\|PHASE2	RECRUITING	2028-11-15	Johns Hopkins Hospital, Baltim... More >>ore, Maryland, 21287, United States Less <<
NCT06666348	Pediatric Low-grade Glioma	PHASE1\|PHASE2	NOT_YET_RECRUITING	1935-01-01	-
NCT04923126	Low-Grade Glioma\|Recurrent Low... More >>-Grade Glioma\|Progressive Low-Grade Glioma Less <<	PHASE1\|PHASE2	RECRUITING	1931-06-01	St. Jude Children's Research H... More >>ospital, Memphis, Tennessee, 38105, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.07mL 0.41mL 0.21mL	10.37mL 2.07mL 1.04mL	20.74mL 4.15mL 2.07mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed